Cidara Therapeutics Stock (NASDAQ:CDTX)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$15.63

52W Range

$10.00 - $24.40

50D Avg

$11.86

200D Avg

$12.98

Market Cap

$106.55M

Avg Vol (3M)

$20.82K

Beta

0.99

Div Yield

-

CDTX Company Profile


Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

69

IPO Date

Apr 15, 2015

Website

CDTX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 23Jun 21Mar 21
Collaboration Revenue$7.61M$32.86M$2.41M

Fiscal year ends in Dec 23 | Currency in USD

CDTX Financial Summary


Dec 23Dec 22Dec 21
Revenue$63.91M$64.29M$49.57M
Operating Income$-24.48M$-29.72M$-42.26M
Net Income$-22.93M$-29.80M$-43.91M
EBITDA$-24.37M$-29.72M$-42.26M
Basic EPS$-0.26$-0.43$-0.84
Diluted EPS$-0.26$-0.43$-0.84

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 17Nov 11, 17 | 4:57 PM

Peer Comparison


TickerCompany
CFRXContraFect Corporation
GLYCGlycoMimetics, Inc.
CTMXCytomX Therapeutics, Inc.
CLSDClearside Biomedical, Inc.